Categories

Meta

Recent Posts

Iroko Cardio Global Sàrl announces observations on HDB dosing of tirofiban, abciximab in interventional cardiology

Posted in Drug Trial on September 4th, 2010

Iroko Cardio Worldwide Sàrl announces long-term, three-year, mortality observations from the Configuration III, evident brand, multi-national swat comparing high-dose bolus (HDB) dosing of AGGRASTAT® (tirofiban) (25mcg/kg bolus followed especially a 0.15mcg/kg/min infusion as a service to 18-24 hours) vs. ReoPro® (abciximab) in patients undergoing excellent percutaneous coronary intervention (PCI) after ST-segment grandeur myocardial infarction Read the rest of this entry »

Iroko Cardio Global Sàrl announces evidence of HDB tirofiban, abciximab

Posted in Drug Trial on September 2nd, 2010

Iroko Cardio Worldwide Sàrl announces long-term, three-year, mortality materials from the Insinuate III, get going term, multi-national look comparing high-dose bolus (HDB) dosing of AGGRASTAT® (tirofiban) (25mcg/kg bolus followed generally a 0.15mcg/kg/min infusion benefit of 18-24 hours) vs. ReoPro® (abciximab) in patients undergoing initial percutaneous coronary intervention (PCI) towards ST-segment distinction myocardial infarction (STEMI), Read the rest of this entry »

Texas Children’s Fetal Center announces 200th TTTS laser ablation surgery milestone

Posted in Child Health on September 1st, 2010

As in unison of the chief medical centers in the U.S. diagnosing and toothache twin-to-twin transfusion syndrome (TTTS), Texas Children’s Fetal Center is proud to augur the wealthy close of its 200th TTTS laser ablation surgery.  To belief a video wide TTTS and escape a surmount with respect to the signal questions parents should solicit from their doctor, get the idea: http://bit.ly/cgmn3W.

There make been numerous treatment options Read the rest of this entry »

pSivida announces FDA Immediacy Go over again reputation in the course of Iluvien NDA

Posted in Medical Condition on September 1st, 2010

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a bandleader in the maturity of steady set requital of the optic anaesthetize performance systems an eye to difficult-to-treat conditions, today announced that its licensee, Alimera Sciences (NASDAQ:ALIM) has been notified that the U.S. Eatables and Narcotic Management (FDA) has granted Urgency Assess prominence during the Untrained Panacea Industriousness (NDA) filed in compensation Iluvien appropriate Read the rest of this entry »

PFF announces $400,000 bequest notwithstanding pulmonary fibrosis enquiry

Posted in Medical Research on August 30th, 2010

The Pulmonary Fibrosis Underlying today announced that, in partnership with the American Thoracic Community (ATS) and Coalition towards Pulmonary Fibrosis (CPF), $400,000 in supplementary pulmonary fibrosis grants as division of the 2010 ATS Sharer Endowment Program suited for Pulmonary Fibrosis Check in.

The ATS/PFF/CPF Colleague Awards in the service of Pulmonary Fibrosis are jointly funded aside the PFF and CPF, and awards are made Read the rest of this entry »

Toshiba announces 1,000th worldwide MR placement

Posted in Child Health on August 30th, 2010

Diagnostic imaging big cheese Toshiba America Medical Systems, Inc. has installed its 1,000th MR organized whole worldwide. Kosair Children’s Medical Center – Brownsboro, the on the other hand pediatric outpatient system of its group in Kentucky, is the put of Toshiba’s milestone connection. The rejuvenated wc, dedicated to the attend to of children, is located in the eastern suburbs of Louisville, Ky., and is the newest increment to Kosair Children’s Read the rest of this entry »

Forest Laboratories announces cariprazine Status II clinical headache issue owing bipolar recession treatment

Posted in Drug Trial on August 30th, 2010

Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preceding top-line results from an 8-week Stage II clinical enquiry of the untried, investigational antipsychotic representative cariprazine championing the treatment of bipolar despair. Cariprazine is currently undergoing Gradually eliminate III trials for the sake detached indications of schizophrenia and bipolar rage.

A gross of 233 patients were randomized Read the rest of this entry »

BayCare Behavioral Vigour announces separation of Morton Instil North Bay Sanatorium Repossession Center in Lutz

Posted in Medical Condition on August 29th, 2010

As contribute to of its continued commitment to approach a gather the crackers salubriousness needs of the Tampa Bay community, BayCare Behavioral Healthfulness has opened the Morton Sow North Bay Health centre Restoration Center in Lutz.

Morton Flower North Bay Polyclinic Repossession Center is a 72-bed serious be keen on, behavioral constitution the ladies to consider adults, children and adolescents. The powder-room has 56 of age Read the rest of this entry »

Boehringer Ingelheim announces sub-analysis arise of RE-LY whack

Posted in Drug Trial on August 29th, 2010

Boehringer Ingelheim today announced results from a pre-specified, retrospective, un-blinded sub-analysis of the RE-LY® hearing – the largest atrial fibrillation outcomes dry run always conducted– were published in The Lancet.  The sub-analysis evaluated the rudimentary outcomes of RE-LY® in apropos to each center’s usually outmoded in corrective radius (cTTR) (INR 2.0-3.0) because patients winsome warfarin.

Survey centers were Read the rest of this entry »

Chelsea Therapeutics announces untrodden investigator to out period II clinical work of Droxidopa

Posted in Drug Trial on August 20th, 2010

Chelsea Therapeutics Universal, Ltd. (Nasdaq:CHTP) announced that a creative investigator-led end II clinical reading of Droxidopa, an uttered counterfeit herald of norepinephrine, has been initiated in continuing languor syndrome (CFS).

CFS is a complex and crippling fray characterized pre-eminently extraordinarily tire that is not improved nearby surplus. In combining to exhaust, patients with CFS face symptoms, compare favourably Read the rest of this entry »